A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine reduced RSV-related lower respiratory tract disease by 63% over three seasons. Protection remained substantial despite waning, with similar efficacy to a two-dose regimen and a favorable safety profile.